Calcium channel blocker toxicity
Enable an AI agent to represent a suspected or confirmed calcium channel blocker toxicity episode, assess its evolving severity and uncertainty, and support clinician-directed decisions.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 17 findings · 27 questions
Exposure and attribution Establishes what calcium channel blocker exposure may have occurred and how strongly it explains the episode.
Agent, formulation, and amount
Captures the implicated product and the evidence supporting its identity and quantity.
Exposure reconstruction
A traceable exposure account with explicit uncertainty about product, formulation, amount, and timing.
- Which calcium channel blocker and formulation are implicated, and what packaging, medication record, witness account, or other evidence supports that identification? provenance
- What amount and exposure interval can be supported, and which estimates depend on assumptions such as missing-tablet counts? measurement
Causal context
Separates calcium channel blocker effects from mixed exposures and non-toxicological explanations.
Attribution and alternatives
Records the evidence for attribution and the competing explanations that remain viable.
- What evidence connects the observed harmful state to calcium channel blocker exposure rather than merely documenting that exposure occurred? boundary
- Which co-exposures, medication interactions, baseline conditions, or acute illnesses could explain or amplify the presentation? boundary
Cardiovascular expression Represents the vascular, myocardial, and electrical components of the observed presentation.
Circulation and pump function
Connects hemodynamic measurements with evidence about perfusion and cardiac function.
Hemodynamic pattern
A time-specific interpretation of the contributions of vascular dysfunction and impaired cardiac performance.
- What do blood-pressure trends, examination, echocardiography, and available hemodynamic measurements show about the current circulatory state? measurement
- What supports a predominantly vascular, myocardial, or mixed interpretation, and what remains unmeasured? boundary
Rate, rhythm, and conduction
Tracks electrical findings and their relationship to circulatory compromise.
Electrical manifestations
Serial rhythm and conduction observations interpreted against baseline status and co-exposures.
- Which rate, rhythm, and conduction abnormalities are documented on serial ECGs or monitoring, and when did they appear? measurement
- Which abnormalities are new and plausibly attributable to this episode, and which may reflect baseline disease, co-ingestants, or treatment? boundary
Metabolism and organ perfusion Connects metabolic observations and organ dysfunction to the evolving toxicity episode.
Metabolic observations
Records glucose, acid-base, lactate, and electrolyte findings with their clinical context.
Metabolic pattern and confounding
Separates observed metabolic abnormalities from assumptions about their cause.
- How do glucose, lactate, pH, and relevant electrolytes change across the episode, with units and sampling times preserved? measurement
- How do diabetes, hypoperfusion, co-exposures, and administered therapies affect interpretation of these measurements? boundary
Organ consequences
Represents neurological, renal, respiratory, and other consequences requiring assessment.
Perfusion and organ dysfunction
Links organ-level observations to possible toxicity-related circulatory compromise while retaining alternatives.
- What changes in mental status, urine output, renal function, oxygenation, or other organ observations accompany the cardiovascular course? measurement
- Which organ abnormalities are attributed to hypoperfusion, another exposure, pre-existing disease, or an intervention, and with what confidence? boundary
Time course and severity Represents onset, progression, supported stability, and possible recurrence.
Onset and observation
Aligns exposure timing with symptom emergence and the rationale for continued assessment.
Temporal risk assessment
A documented interpretation of the episode's timing without assuming that an early normal examination excludes later toxicity.
- When were the last known well state, earliest symptoms, first abnormalities, and subsequent deterioration relative to the possible exposure interval? measurement
- Which applicable toxicology guidance supports the observation plan for this agent, formulation, exposure pattern, and current presentation? provenance
Severity and recurrence
Tracks clinical severity using observations, organ effects, and required support.
Dynamic severity state
A time-specific severity judgment that distinguishes deterioration, treatment-supported stability, and recovery.
- Which observed abnormalities, organ consequences, and support requirements justify the current severity assessment? definition
- Has deterioration or recurrence followed apparent improvement or reduction of support, and what evidence supports its proposed cause? measurement
Clinical actions and resolution Records clinician-directed actions, their rationale, monitored effects, and the basis for ending acute episode management.
Interventions and response
Connects exposure-directed and physiological treatments to indications, oversight, and observed effects.
Treatment decision and effect
A record of selected or deferred interventions, including calcium, high-dose insulin therapy, vasoactive support, and advanced support when considered by the treating team.
- What clinical indication, toxicology recommendation, or protocol supports each intervention selected or deferred, and who owns the decision? action
- What intended response and adverse effects were monitored, and how do simultaneous interventions limit attribution of improvement or harm? measurement
Recovery and handoff
Defines the evidence for sustained recovery and the information required at transfer or disposition.
Resolution evidence
A documented basis for episode resolution or continued care that accounts for residual abnormalities and ongoing support.
- What sustained clinical findings and applicable observation criteria support resolution, including the period after relevant support is withdrawn? boundary
- Which residual organ effects, exposure uncertainties, medication-review needs, and recurrence concerns must be communicated at handoff? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of Calcium channel blocker toxicity this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Information and virtual systems
- Entry kind
- thing
- Plane
- INF
- Domain
- INF.MED
What it is Filled
Calcium channel blocker toxicity is a poisoning syndrome caused by excessive calcium channel antagonist effects, principally on vascular smooth muscle, cardiac conduction and contractility, and pancreatic insulin secretion, potentially producing life-threatening circulatory failure.
In scope
- Suspected or confirmed toxicity attributable to one or more calcium channel blockers
- Exposure circumstances, formulation, timing, and uncertainty relevant to the episode
- Cardiovascular, metabolic, and organ-perfusion abnormalities assessed in context
- Mixed exposures and competing explanations that affect causal attribution
- Clinical escalation, intervention response, recurrence, and episode resolution
Out of scope
- Chemical identity, manufacture, and general pharmacology of individual calcium channel blockers
- Routine prescribing and monitoring without suspected toxicity
- Independent models of shock, arrhythmia, or organ injury beyond their role in this episode
- Full toxicology models for co-ingestants
- Longitudinal psychiatric assessment and intentional self-harm care
- Institution-specific treatment protocols and autonomous medication dosing
Why it exists Filled
Enable an AI agent to represent a suspected or confirmed calcium channel blocker toxicity episode, assess its evolving severity and uncertainty, and support clinician-directed decisions.
Distinguishing features Filled
- Requires a supported or explicitly uncertain causal connection between calcium channel blocker exposure and a harmful physiological state; exposure alone does not establish toxicity.
- Separates expected therapeutic effects and mild adverse effects from a toxicity episode using documented clinical interpretation rather than a universal dose cutoff.
- Tests attribution against beta-blocker toxicity and other causes of hypotension or bradycardia; no single heart-rate, glucose, or electrocardiographic finding is treated as diagnostic.
- Distinguishes predominantly vascular, myocardial, conduction-related, and mixed presentations rather than requiring one fixed toxidrome.
- Evaluates findings against exposure timing and formulation so an initially reassuring assessment is not automatically treated as resolution.
What robots and AI may and may not do Filled
Must not
- Diagnose poisoning or advise on treatment for a person.
- Advise on dosing these medicines.
- Provide information that helps anyone harm themselves or others.
- Delay emergency help.
Only with a human decision
- All treatment decisions, made by clinicians.
May
- Explain what calcium channel blocker toxicity is and its warning signs from medical sources.
- Direct anyone with suspected poisoning to emergency care or a poison centre.
Moral aspects Filled
- These medicines are widely prescribed, and poisoning, including in children, can be fatal.
- Overdose information must focus on safety and treatment.
Who is affected
- Patients
- Children who swallow medicines
- Caregivers
Owners Filled
Steward
Nobody owns the condition; the treating clinician answers for each patient.
Links to other meta-models Filled
parent
- Q387175 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.calcium-channel-blocker-toxicity
- Wikidata: Q17071650 (https://www.wikidata.org/wiki/Q17071650)
Direct properties not applicable Not applicable
- Causal attribution status: suspected | supported | clinician-confirmed | disputed | excluded
- Implicated agent and formulation: Links to drug identities, product records, and immediate-release, modified-release, or unknown formulation
- Exposure estimate: mg, mg/kg when justified, or an explicit range; unknown permitted
- Exposure timing: Timestamp or interval with confidence; elapsed hours relative to a specified assessment
- Exposure circumstance: acute excess | repeated excess | therapeutic-use accumulation or interaction | administration error | uncertain
- Hemodynamic phenotype: predominantly vascular | predominantly myocardial | predominantly conduction-related | mixed | undetermined; assessment time and evidence required
- Cardiovascular observations: Heart rate in beats/min, blood pressure in mmHg, ECG intervals in ms, and linked rhythm interpretation
- Metabolic and perfusion observations: Glucose in mmol/L or mg/dL, lactate in mmol/L, pH, and linked clinical perfusion observations
- Clinical trajectory: not yet clinically manifest | worsening | stable with support | improving | recurrent | resolved | uncertain
- Intervention dependence: Links to active interventions, their timing, monitoring, and clinician-assessed dependence
Plane INF: no invented physical properties.
Recognition optional Filled
- Not visible directly; signs include low blood pressure, slow heart rate and collapse.
- Diagnosed by clinical assessment, heart rhythm tests and history of ingestion.
Capabilities and actions required Filled
- Assemble a time-aligned account of exposure evidence, clinical findings, and interventions.
- Identify missing exposure details and unresolved alternative causes that limit attribution.
- Track deterioration, mixed physiological patterns, and possible recurrence for clinician review.
- Compare observed intervention responses while identifying simultaneous treatments and confounding.
- Prepare a structured toxicology consultation or care handoff with uncertainty preserved.
- Evaluate whether documented recovery and disposition criteria have been met under an applicable clinical protocol.
Hazards and failure modes required Filled
- Severe low blood pressure and shock.
- Delayed effects from extended-release tablets can be missed.
Standards and interfaces required Filled
- ICD-10 category T46.1, Poisoning by calcium-channel blockers, issued by the World Health Organization, classifies poisoning episodes involving these medicines.
Context of use required Filled
- Calcium channel blocker toxicity is encountered in emergency medicine, clinical toxicology and intensive care following excessive drug exposure.
- It is represented in clinical records to support assessment of circulatory compromise, changes over time and uncertainty about the exposure.
- Poison information services and treating clinicians use the diagnosis to coordinate specialist assessment and ongoing care.
Sources Filled
- Wikidata item Q17071650: Calcium channel blocker toxicity - identity and sense of the item
- Wikipedia: Calcium channel blocker toxicity - general description of the item
Open questions
- Which authoritative definitions best distinguish calcium channel blocker toxicity from expected therapeutic effects and non-toxic adverse reactions?
- Which severity framework is sufficiently validated across different calcium channel blockers, age groups, and mixed exposures?
- Which agent- and formulation-specific evidence should determine observation and recovery criteria when exposure amount or timing is uncertain?
- How reliably can available bedside evidence separate vascular and myocardial contributions, and how should unresolved mixed physiology be represented?
- Which current consensus sources should govern treatment indications, escalation, and monitoring, and where do evidence limitations or disagreements remain?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q17071650/spec.json